Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
3상
진행 중(모집 완료)
NCT04223856
| 대상 질환 | Urothelial Cancer |
|---|
| 임상 단계 | 3상 |
|---|
| 스폰서 | Astellas Pharma Global Development, Inc. |
|---|
| 상태 | 진행 중(모집 완료) |
|---|
| 참여자 수 | 886 명 |
|---|
| 중재(약물) | Enfortumab vedotin, Pembrolizumab, Cisplatin, Carboplatin, Gemcitabine |
|---|
| 시작일 | 2020년 3월 30일 |
|---|
| 완료일 | 2023년 8월 8일 |
|---|
| 결과 공개일 | 2024년 9월 27일 |
|---|
요약
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have cancer that has spread from their urinary system to other parts of their body.
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Blinded Independent Central Review (BICR)
From the date of randomization to first documentation of PD or death due to any cause, whichever occurred first (maximum exposure to treatment was up to 39.2 months) · Months
| Enfortumab Vedotin + Pembrolizumab | 12.5 Months |
|---|
| Standard of Care | 6.3 Months |
|---|
| p-value | <0.00001 |
|---|
| Hazard Ratio (HR) | 0.450 (95% CI 0.377–0.538) |
|---|
Overall Survival (OS)
From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum exposure to treatment was up to 39.2 months) · Months
| Enfortumab Vedotin + Pembrolizumab | 31.5 Months |
|---|
| Standard of Care | 16.1 Months |
|---|
| p-value | <0.00001 |
|---|
| Hazard Ratio (HR) | 0.468 (95% CI 0.376–0.582) |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.